Back to News
Market Impact: 0.35
101 Therapeutics to Present Phase 2/3 Data on Macrophage-Targeted, Steroid-Sparing Glucocorticoid 101-PGC-005 at ACR Convergence 2026
Source: Business Wire
Healthcare & Biotech
CD206-targeted glucocorticoid 101-PGC-005 reportedly beat dexamethasone in a 309-patient Phase 2/3 trial, with a reported hazard ratio of 2.31. Steroid-sparing data are scheduled for presentation at ACR Poster 0122 on Nov. 8; the brief does not provide further efficacy or safety details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?
- Disc Medicine prices $450 million stock offering at $75/share
- Alpha Teknova stock tumbles on public offering announcement